Wanbury Limited (NSE: WANBURY)
India
· Delayed Price · Currency is INR
238.25
+10.15 (4.45%)
Jan 14, 2025, 3:29 PM IST
Wanbury Revenue
Wanbury had revenue of 1.61B INR in the quarter ending September 30, 2024, with 11.58% growth. This brings the company's revenue in the last twelve months to 5.77B, up 5.04% year-over-year. In the fiscal year ending March 31, 2024, Wanbury had annual revenue of 5.76B with 15.21% growth.
Revenue (ttm)
5.77B
Revenue Growth
+5.04%
P/S Ratio
n/a
Revenue / Employee
3.87M
Employees
1,491
Market Cap
7.74B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 5.76B | 760.03M | 15.21% |
Mar 31, 2023 | 5.00B | -115.39M | -2.26% |
Mar 31, 2022 | 5.11B | 1.19B | 30.23% |
Mar 31, 2021 | 3.93B | 250.63M | 6.82% |
Mar 31, 2020 | 3.67B | -239.19M | -6.11% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 503.08B |
Divi's Laboratories | 86.14B |
Cipla | 262.64B |
Mankind Pharma | 110.18B |
Zydus Lifesciences | 214.84B |
Apollo Hospitals Enterprise | 204.69B |
Aurobindo Pharma | 302.95B |
Alkem Laboratories | 128.32B |
Wanbury News
- 12 days ago - Wanbury completes successful ANVISA audit at Tanuku facility - Business Upturn